Long-term outcomes after percutaneous cryoablation of abdominal wall endometriosis.

Abstract

To retrospectively evaluate the long-term outcomes after percutaneous cryoablation of abdominal wall endometriosis (AWE). The Institutional Review Board approved this retrospective observational review of 40 consecutive patients, of a median age of 37years (interquartile range [IQR] 32-40years), presenting with a total of 52 symptomatic AWE nodules. All patients underwent cryoablation between January 2013 and May 2022 with a minimum follow-up period of 12months. Outcomes were assessed using a visual analog scale (VAS) that measured pain, as well as by magnetic resonance imaging (MRI). The pain-free survival rates were derived using the Kaplan-Meier estimator. Adverse events were analyzed and graded using the classification system of the Cardiovascular and Interventional Radiological Society of Europe. The median follow-up time was 40.5months (IQR 26.5-47.2months). The median VAS score before cryoablation was 8 (IQR 7-9). Complete relief of symptoms was documented in 80% (32/40) of patients at 3months after initial cryoablation and correlated with the absence of residual endometriosis nodules on MRI. The median pain-free survival rates were 89.2% [95% CI, 70.1-96.4%] at 36months and 76.8% [95% CI, 55.3-83.8%] after 60months. No patient or lesion characteristics were found to be prognostic of failure. No major adverse events or side effects were reported in long term. Cryoablation safely and effectively afforded long-term pain relief for patients with AWE nodules. AWE cryoablation was found to be safe and effective in the long-term. • Cryoablation is highly effective with 80% of patients experiencing complete relief of AWE symptoms after a single procedure. • Cryoablation is safe without long-term adverse events or side effects. • The median pain-free survival rates are 89.2% at 36months and 76.8% at 60months.